IL13 and hepatocellular carcinoma: Recently, Jilkova et al., indicated that the levels of IL‐4 and IL‐13 were significantly higher, and the levels of 4‐1BB and PDL2 were significantly lower, in patients who developed HCC after achieving SVR with DAA treatment compared to those who did not.